MLANA and melanoma: We have previously shown that subcutaneous vaccination of stage III–IV melanoma patients with the mixture of Melan-A peptide, CpG-containing oligodeoxynucleotide, and Montanide induces large numbers of circulating Melan-A-specific CD8+ T cells in the majority of patients treated (24).